Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population
RC Zhu, K Rattanakorn, S Pham, D Mallam… - Colorectal …, 2017 - Future Medicine
RC Zhu, K Rattanakorn, S Pham, D Mallam, T McIntyre, MO Salifu, I Youssef, SI McFarlane…
Colorectal cancer, 2017•Future MedicineWe assessed the association of metformin use with survival in colorectal cancer in a
population consists mostly of African-American and Afro-Caribbean patients. We identified
585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and
nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent
of disease. Overall, DMs with metformin use (D+ M+) have better overall survival than both
DMs without metformin use (D+ M∼) and nondiabetics (D∼ M∼), with a mean survival of …
population consists mostly of African-American and Afro-Caribbean patients. We identified
585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and
nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent
of disease. Overall, DMs with metformin use (D+ M+) have better overall survival than both
DMs without metformin use (D+ M∼) and nondiabetics (D∼ M∼), with a mean survival of …
We assessed the association of metformin use with survival in colorectal cancer in a population consists mostly of African-American and Afro-Caribbean patients. We identified 585 colorectal cancer patients, 167 (28.6%) and 418 (71.5%) were as diabetic (DM) and nondiabetic, respectively. The diagnosis of diabetes did not impact cancer survival or extent of disease. Overall, DMs with metformin use (D+M+) have better overall survival than both DMs without metformin use (D+M∼) and nondiabetics (D∼M∼), with a mean survival of 109.9 months compared with 95.7 and 106.1 months, respectively (log-rank p < 0.05). The use of metformin shows significant reduction of risk of mortality compared with nonusers (hazard ratio: 0.34; 95% CI: 0.15–0.81; p = 0.01). Use of insulin and status of diabetes did not have a significant impact on overall cancer survival.
Future Medicine